The Trial Phase Ladder
Pre-clinical
Lab + animal studies. Not really investable unless you have specialized expertise.
Phase 1 (safety)
- Usually 20-100 healthy volunteers
- Duration: several months
- Goal: determine safe dose, identify side effects
- Success rate: ~60% proceed to Phase 2
Phase 2 (efficacy + dose-finding)
- 100-500 patients with the target condition
- Duration: several months to 2 years
- Goal: demonstrate efficacy signal, optimize dose
- Success rate: ~30-40% proceed to Phase 3
Phase 3 (pivotal efficacy)
- Hundreds to thousands of patients
- Duration: 1-4 years
- Goal: statistically significant efficacy + safety profile
- Success rate: ~60% achieve primary endpoints
NDA / BLA filing
Sponsor files with FDA; PDUFA date set.
Post-approval Phase 4
Real-world safety and long-term efficacy monitoring.
Which Readouts Move Stocks Most
Phase 2 efficacy readouts
Often the biggest single mover. Phase 2 establishes whether a drug actually works. Stocks can double on positive Phase 2 or halve on a miss.
Phase 3 primary endpoint hit/miss
Less surprising than Phase 2 because Phase 2 has already de-risked the thesis, but stocks still move 15-40% on Phase 3 readouts.
Subgroup analyses
Modern biotechs often slice Phase 3 data by subpopulation. A miss on primary with a hit on subgroup can produce positive reactions if the subgroup is large and commercially meaningful.
Risk Factors
Primary endpoint design
Was it pre-specified? Was it clinically meaningful? FDA scrutinizes endpoints that look p-hacked.
Sample size and power
Small trials may miss effects even when drugs work. Large trials may detect tiny effects that aren't clinically meaningful.
Safety signals
Even positive efficacy data can be overshadowed by safety signals (liver toxicity, cardiovascular events).
Comparator arm
Placebo-controlled trials produce cleaner signals than active-comparator; active-comparator trials set a higher bar.
Market Reactions
- Phase 1 readouts: usually muted unless unexpectedly positive or safety concerns
- Phase 2 readouts: highest volatility single-day moves
- Phase 3 readouts: setup often priced in; surprises still big
- PDUFA decisions: see separate guide
Risk Management
- Use options to hedge if concentrated
- Consider selling half on major binary readouts
- Watch for insider selling in the weeks before readouts
- Don't average down after binary failures — the de-rating is usually deserved
Monitoring Tools
- ClinicalTrials.gov for trial design
- FDA advisory committees for approval guidance
- Conference calls quarterly for pipeline updates
- [/topic/biotech-fda](/topic/biotech-fda) for live news
Key Takeaways
- Phase 2 moves stocks most (first real efficacy signal)
- Phase 3 and PDUFA are less surprising but still high-volatility
- Endpoint design, safety signals, and comparator arm all matter
- Size positions for binary outcomes
See [/stocks/LLY](/stocks/LLY), [/stocks/MRNA](/stocks/MRNA).